Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Targeted Therapy + PD-1 Inhibitor in Postoperative Hepatocellular Carcinoma With Microvascular Invasion
NCT07790419Phase 4Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 4 trial of oxaliplatin, fluorouracil, donafenib, lenvatinib, Rivoceranib in hepatocellular carcinoma (HCC). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracildonafeniblenvatinibRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07790419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07790419.